<?xml
version="1.0" encoding="utf-8"?>
<rss version="2.0" 
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
>

<channel xml:lang="fr">
	<title>Joseph Larmarange</title>
	<link>https://joseph.larmarange.net/</link>
	<description>D&#233;mographe en sant&#233; publique, directeur de recherche HDR &#224; l'IRD,directeur adjoint du Ceped (UMR 196 Universit&#233; Paris Cit&#233;, IRD, Universit&#233; Sorbonne Paris Nord, Inserm)</description>
	<language>fr</language>
	<generator>SPIP - www.spip.net</generator>
	<atom:link href="https://www.joseph.larmarange.net/spip.php?id_mot=92&amp;page=backend" rel="self" type="application/rss+xml" />

	<image>
		<title>Joseph Larmarange</title>
		<url>https://www.joseph.larmarange.net/local/cache-vignettes/L144xH52/joseph_larmarange_site-6e82f.svg?1649686173</url>
		<link>https://joseph.larmarange.net/</link>
		<height>52</height>
		<width>144</width>
	</image>



<item xml:lang="en">
		<title>Syndromic and biological screening for sexually transmitted infections in female sex workers in C&#244;te d'Ivoire: the ANRS 12381 PRINCESSE cohort study</title>
		<link>https://www.joseph.larmarange.net/syndromic-and-biological-screening</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/syndromic-and-biological-screening</guid>
		<dc:date>2025-03-13T17:07:15Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>en</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>C&#244;te d'Ivoire</dc:subject>
		<dc:subject>PRINCESSE</dc:subject>
		<dc:subject>D&#233;pistage</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>IST (Infections Sexuellement Transmissibles)</dc:subject>
		<dc:subject>Travail du sexe</dc:subject>
		<dc:subject>VIH / SIDA</dc:subject>

		<description>
&lt;p&gt;Authors &lt;br class='autobr' /&gt;
Marcellin N'zebo Nouaman, Patrick Ahuatchi Coffie, Aline Agoua, Cl&#233;mence Z&#233;bago, Herv&#233; Dao, Evelyne Kissi, S&#233;verin Lenaud, Mian Anatole, Valentine Becquet, M&#233;lanie Plazy, Fran&#231;ois Dabis, Serge Eholie, Joseph Larmarange for the ANRS 12381 Princesse Study group &lt;br class='autobr' /&gt;
Abstract &lt;br class='autobr' /&gt;
Background: Female sex workers (FSWs) are at high risk of contracting STIs, in particular in Sub-Saharan Africa. The implementation of oral HIV pre-exposure prophylaxis provided an opportunity to draw attention to&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Publications-11-" rel="directory"&gt;Publications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-Cote-d-Ivoire-+" rel="tag"&gt;C&#244;te d'Ivoire&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PRINCESSE-+" rel="tag"&gt;PRINCESSE&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Depistage-+" rel="tag"&gt;D&#233;pistage&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-IST-Infections-Sexuellement-+" rel="tag"&gt;IST (Infections Sexuellement Transmissibles)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Travail-du-sexe-+" rel="tag"&gt;Travail du sexe&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH111/princesse-9c71c.jpg?1741888608' class='spip_logo spip_logo_right' width='150' height='111' alt=&#034;&#034; /&gt;
		&lt;div class='rss_texte'&gt;&lt;div class=&#034;hal-resultats&#034;&gt; &lt;div class=&#034;hal-resultat hal-resultat-4990249&#034;&gt; &lt;div class=&#034;hal-thumb&#034;&gt;&lt;a href=&#034;https://hal.science/hal-04990223v1/document&#034; class=&#034;hal-thumb-link&#034;&gt;&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L53xH75/thumb-4596acf7-a3a62.png?1741981009' alt=&#034;Image document&#034; width='53' height='75' /&gt; &lt;/a&gt;&lt;/div&gt; &lt;div class=&#034;hal-preview&#034;&gt; &lt;a href=&#034;https://hal.science/hal-04990223v1&#034; class=&#034;hal-titre&#034;&gt; &lt;h3 class=&#034;hal-titre-heading&#034;&gt;Syndromic and biological screening for sexually transmitted infections in female sex workers in C&#244;te d'Ivoire: the ANRS 12381 PRINCESSE cohort study&lt;/h3&gt; &lt;/a&gt; &lt;div class=&#034;hal-auteurs&#034;&gt; &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Marcellin+N%E2%80%99zebo+Nouaman&#034; class=&#034;hal-auteur&#034;&gt;Marcellin N'zebo Nouaman&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Patrick+Ahuatchi+Coffie&#034; class=&#034;hal-auteur&#034;&gt;Patrick Ahuatchi Coffie&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Aline+Agoua&#034; class=&#034;hal-auteur&#034;&gt;Aline Agoua&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Cl%C3%A9mence+Z%C3%A9bago&#034; class=&#034;hal-auteur&#034;&gt;Cl&#233;mence Z&#233;bago&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Herv%C3%A9+Dao&#034; class=&#034;hal-auteur&#034;&gt;Herv&#233; Dao&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Evelyne+Kissi&#034; class=&#034;hal-auteur&#034;&gt;Evelyne Kissi&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=S%C3%A9verin+Lenaud&#034; class=&#034;hal-auteur&#034;&gt;S&#233;verin Lenaud&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Mian+Anatole&#034; class=&#034;hal-auteur&#034;&gt;Mian Anatole&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Valentine+Becquet&#034; class=&#034;hal-auteur&#034;&gt;Valentine Becquet&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/q/*/authIdHal_s/melanie-plazy&#034; class=&#034;hal-auteur&#034;&gt;M&#233;lanie Plazy&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authIdPerson_i=7426731196998&#034; class=&#034;hal-auteur&#034;&gt;Fran&#231;ois Dabis&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/?q=*&amp;authFullName_s=Serge+Eholie&#034; class=&#034;hal-auteur&#034;&gt;Serge Eholie&lt;/a&gt; , &lt;a href=&#034;https://hal.science/search/index/q/*/authIdHal_s/joseph-larmarange&#034; class=&#034;hal-auteur&#034;&gt;Joseph Larmarange&lt;/a&gt; &lt;/div&gt; &lt;div class=&#034;hal-citation&#034;&gt;&lt;i&gt;Frontiers in Public Health&lt;/i&gt;, 2025, 13, &lt;a target=&#034;_blank&#034; href=&#034;https://dx.doi.org/10.3389/fpubh.2025.1535122&#034; rel=&#034;noreferrer noopener&#034;&gt;&#10216;10.3389/fpubh.2025.1535122&#10217;&lt;/a&gt;&lt;/div&gt; &lt;div class=&#034;hal-typedoc hal-typedoc-art&#034;&gt;Article dans une revue&lt;/div&gt; &lt;div class=&#034;hal-links&#034;&gt; &lt;a href=&#034;https://hal.science/hal-04990223v1&#034; class=&#034;hal-link hal-link-hal&#034;&gt;hal-04990223&lt;/a&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;h2 class=&#034;spip&#034;&gt;
Authors&lt;/h2&gt;
&lt;p&gt;Marcellin N'zebo Nouaman, Patrick Ahuatchi Coffie, Aline Agoua, Cl&#233;mence Z&#233;bago, Herv&#233; Dao, Evelyne Kissi, S&#233;verin Lenaud, Mian Anatole, Valentine Becquet, M&#233;lanie Plazy, Fran&#231;ois Dabis, Serge Eholie, Joseph Larmarange for the ANRS 12381 Princesse Study group&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Abstract&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;Background:&lt;/strong&gt; Female sex workers (FSWs) are at high risk of contracting STIs, in particular in Sub-Saharan Africa. The implementation of oral HIV pre-exposure prophylaxis provided an opportunity to draw attention to the sexual health needs of FSWs. Innovative strategies to screen for and reduce the burden of STIs is thus a priority. This study describes STI screening among FSWs enrolled in the PRINCESSE project in C&#244;te d'Ivoire.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Methods:&lt;/strong&gt; The PRINCESSE project (2019&#8211;2023) was an interventional cohort of FSWs &#8805;18&#8239;years, evaluating a comprehensive, community-based sexual and reproductive health care package, including the management of STIs, offered through mobile clinics operating on prostitution sites in San Pedro area. HIV testing and syndromic STI testing were offered at baseline and every 3&#8239;months. Biological testing of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) was offered annually. Clinical forms included sociodemographic, behavioral and sex-work-related characteristics. We describe baseline characteristics, coverage of clinical examination, and vaginal, anal swab collection. Social, behavioral and sex work-related factors associated with an STI syndromic diagnosis were explored. A multivariable logistic regression model was used to identify factors associated with diagnosing a symptomatic STI.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Results:&lt;/strong&gt; 489 FSWs were included in the PRINCESSE cohort. Median age was 29&#8239;years (24&#8211;35&#8239;years), 28.6% had had sex without a condom in the last 7&#8239;days. The prevalence of HIV at baseline was 10.5%. Only one case of HIV seroconversion was observed during the project. The most frequent symptom was ano-vaginal discharge (19.1%). The prevalence of STI based on clinical symptoms was 26.6%. The proportion of vaginal swab samples for which the PCR result was positive was 8.0% for CT and 4.0% for NG. Only age remained significantly associated with diagnosing a symptomatic STI in the multivariable analysis.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Conclusion:&lt;/strong&gt; This study revealed a high prevalence of HIV and STIs, similar to national estimates among FSWs enrolled in a sexual health cohort. Screening for these generically asymptomatic bacterial STIs must be combined with the syndromic approach used in key populations, especially with the introduction of new PrEP programs, to reduce the exposure of individuals in these populations to STIs.&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>D&#233;crire les &#233;pid&#233;mies, Comprendre les populations&#160;: une d&#233;mographie du VIH en Afrique subsaharienne</title>
		<link>https://www.joseph.larmarange.net/hdr</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/hdr</guid>
		<dc:date>2022-10-14T06:38:12Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>Afrique subsaharienne</dc:subject>
		<dc:subject>ATLAS</dc:subject>
		<dc:subject>CAP-CoV-Soignants-BF</dc:subject>
		<dc:subject>DOD-CI (ANRS 12287 / 12323)</dc:subject>
		<dc:subject>ELIHoS (ANRS 12139)</dc:subject>
		<dc:subject>PrEP CI (ANRS 12361)</dc:subject>
		<dc:subject>Pr&#233;valences du VIH (ANRS 12114)</dc:subject>
		<dc:subject>prevR</dc:subject>
		<dc:subject>PRINCESSE</dc:subject>
		<dc:subject>TasP (ANRS 12249)</dc:subject>
		<dc:subject>Afrique du Sud</dc:subject>
		<dc:subject>Burkina Faso</dc:subject>
		<dc:subject>C&#244;te d'Ivoire</dc:subject>
		<dc:subject>Mali</dc:subject>
		<dc:subject>S&#233;n&#233;gal</dc:subject>
		<dc:subject>Acc&#232;s aux soins</dc:subject>
		<dc:subject>Analyse de s&#233;quences</dc:subject>
		<dc:subject>Approches biographiques</dc:subject>
		<dc:subject>Approches communautaires</dc:subject>
		<dc:subject>Autotests VIH</dc:subject>
		<dc:subject>Cartographie</dc:subject>
		<dc:subject>Cascade des soins</dc:subject>
		<dc:subject>Comparaison de cohortes</dc:subject>
		<dc:subject>Comportements sexuels</dc:subject>
		<dc:subject>D&#233;mographie</dc:subject>
		<dc:subject>D&#233;pistage</dc:subject>
		<dc:subject>EDS (Enqu&#234;tes D&#233;mographiques et de Sant&#233;)</dc:subject>
		<dc:subject>Enqu&#234;tes par t&#233;l&#233;phone</dc:subject>
		<dc:subject>Enseignement acad&#233;mique</dc:subject>
		<dc:subject>Lien vers les soins</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Essais cliniques</dc:subject>
		<dc:subject>Estimateurs &#224; noyau (kernel density estimation)</dc:subject>
		<dc:subject>Femmes enceintes</dc:subject>
		<dc:subject>Financement des programmes</dc:subject>
		<dc:subject>H&#233;patites virales</dc:subject>
		<dc:subject>Homo / Bisexualit&#233;s</dc:subject>
		<dc:subject>Identit&#233;s sexuelles</dc:subject>
		<dc:subject>Incidence du VIH</dc:subject>
		<dc:subject>Interpolation spatiale</dc:subject>
		<dc:subject>IST (Infections Sexuellement Transmissibles)</dc:subject>
		<dc:subject>Itin&#233;raires th&#233;rapeutiques</dc:subject>
		<dc:subject>Masculinit&#233;s</dc:subject>
		<dc:subject>M&#233;nages</dc:subject>
		<dc:subject>Mesure d'impact</dc:subject>
		<dc:subject>Mesure des indicateurs</dc:subject>
		<dc:subject>M&#233;thodologie</dc:subject>
		<dc:subject>Migrations</dc:subject>
		<dc:subject>Observatoire de population</dc:subject>
		<dc:subject>Partenaires sexuel(le)s</dc:subject>
		<dc:subject>PrEP</dc:subject>
		<dc:subject>Pr&#233;valence du VIH</dc:subject>
		<dc:subject>Pr&#233;vention</dc:subject>
		<dc:subject>Prise en charge</dc:subject>
		<dc:subject>Recherche interventionnelle</dc:subject>
		<dc:subject>Recherche participative/communautaire</dc:subject>
		<dc:subject>Recrutement &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;boules de neige&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;</dc:subject>
		<dc:subject>Repr&#233;sentations / Perceptions</dc:subject>
		<dc:subject>Repr&#233;sentativit&#233; et Biais</dc:subject>
		<dc:subject>Sant&#233; publique</dc:subject>
		<dc:subject>Sant&#233; sexuelle</dc:subject>
		<dc:subject>Structure des populations</dc:subject>
		<dc:subject>Structures de sant&#233;</dc:subject>
		<dc:subject>Surveillance sentinelle</dc:subject>
		<dc:subject>T&#233;l&#233;phones mobiles</dc:subject>
		<dc:subject>Temporalit&#233;s</dc:subject>
		<dc:subject>Traitement antir&#233;troviral (ARV)</dc:subject>
		<dc:subject>Travail du sexe</dc:subject>
		<dc:subject>Treatment as Prevention (TasP)</dc:subject>
		<dc:subject>Universal Test &amp; Treat (UTT)</dc:subject>
		<dc:subject>Usager&lt;span aria-hidden='true'&gt;&#183;&lt;/span&gt;e&lt;span aria-hidden='true'&gt;&#183;&lt;/span&gt;s de drogue</dc:subject>
		<dc:subject>VIH / SIDA</dc:subject>

		<description>
&lt;p&gt;Habilitation &#224; Diriger des Recherches soutenue le 12&#160;octobre 2012 par Joseph Larmarange &#224; l'Universit&#233; Paris Cit&#233;. &lt;br class='autobr' /&gt; D&#233;crire les &#233;pid&#233;mies, Comprendre les populations&#160;: une d&#233;mographie du VIH en Afrique subsaharienne &lt;br class='autobr' /&gt; Joseph Larmarange D&#233;mographie. Universit&#233; Paris Cit&#233;, 2022 HDR tel-03814024&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Publications-11-" rel="directory"&gt;Publications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-Afrique-subsaharienne-+" rel="tag"&gt;Afrique subsaharienne&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-ATLAS-+" rel="tag"&gt;ATLAS&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-CAP-CoV-Soignants-BF-+" rel="tag"&gt;CAP-CoV-Soignants-BF&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-DOD-CI-ANRS-12287-+" rel="tag"&gt;DOD-CI (ANRS 12287 / 12323)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-ELIHoS-ANRS-12139-+" rel="tag"&gt;ELIHoS (ANRS 12139)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PrEP-CI-ANRS-12361-+" rel="tag"&gt;PrEP CI (ANRS 12361)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevalences-du-VIH-ANRS-12114-+" rel="tag"&gt;Pr&#233;valences du VIH (ANRS 12114)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-prevR-+" rel="tag"&gt;prevR&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PRINCESSE-+" rel="tag"&gt;PRINCESSE&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-TasP-ANRS-12249-97-+" rel="tag"&gt;TasP (ANRS 12249)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Afrique-du-Sud-+" rel="tag"&gt;Afrique du Sud&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Burkina-Faso-+" rel="tag"&gt;Burkina Faso&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cote-d-Ivoire-+" rel="tag"&gt;C&#244;te d'Ivoire&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Mali-+" rel="tag"&gt;Mali&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Senegal-+" rel="tag"&gt;S&#233;n&#233;gal&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Acces-aux-soins-+" rel="tag"&gt;Acc&#232;s aux soins&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Analyse-de-sequences-+" rel="tag"&gt;Analyse de s&#233;quences&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Approches-biographiques-+" rel="tag"&gt;Approches biographiques&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Approches-communautaires-+" rel="tag"&gt;Approches communautaires&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Autotests-VIH-+" rel="tag"&gt;Autotests VIH&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cartographie-+" rel="tag"&gt;Cartographie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cascade-des-soins-+" rel="tag"&gt;Cascade des soins&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Comparaison-de-cohortes-+" rel="tag"&gt;Comparaison de cohortes&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Comportements-sexuels-+" rel="tag"&gt;Comportements sexuels&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Demographie-+" rel="tag"&gt;D&#233;mographie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Depistage-+" rel="tag"&gt;D&#233;pistage&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-EDS-Enquetes-Demographiques-et-de-+" rel="tag"&gt;EDS (Enqu&#234;tes D&#233;mographiques et de Sant&#233;)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Enquetes-par-telephone-+" rel="tag"&gt;Enqu&#234;tes par t&#233;l&#233;phone&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Enseignement-academique-+" rel="tag"&gt;Enseignement acad&#233;mique&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Entree-en-soins-+" rel="tag"&gt;Lien vers les soins&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Essais-cliniques-+" rel="tag"&gt;Essais cliniques&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Estimateurs-a-noyau-kernel-density-+" rel="tag"&gt;Estimateurs &#224; noyau (kernel density estimation)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Femmes-enceintes-+" rel="tag"&gt;Femmes enceintes&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Financement-des-programmes-+" rel="tag"&gt;Financement des programmes&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Hepatites-virales-+" rel="tag"&gt;H&#233;patites virales&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-MSM-Homo-Bisexualite-+" rel="tag"&gt;Homo / Bisexualit&#233;s&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Identites-sexuelles-+" rel="tag"&gt;Identit&#233;s sexuelles&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Incidence-du-VIH-+" rel="tag"&gt;Incidence du VIH&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Interpolation-spatiale-+" rel="tag"&gt;Interpolation spatiale&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-IST-Infections-Sexuellement-+" rel="tag"&gt;IST (Infections Sexuellement Transmissibles)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Itineraires-therapeutiques-+" rel="tag"&gt;Itin&#233;raires th&#233;rapeutiques&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Masculinites-+" rel="tag"&gt;Masculinit&#233;s&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Menages-+" rel="tag"&gt;M&#233;nages&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Mesure-d-impact-+" rel="tag"&gt;Mesure d'impact&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Validite-de-la-mesure-+" rel="tag"&gt;Mesure des indicateurs&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Methodologie-+" rel="tag"&gt;M&#233;thodologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Migrations-+" rel="tag"&gt;Migrations&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Observatoire-de-population-+" rel="tag"&gt;Observatoire de population&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Partenaires-sexuel-le-s-+" rel="tag"&gt;Partenaires sexuel(le)s&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PrEP-+" rel="tag"&gt;PrEP&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevalence-du-VIH-+" rel="tag"&gt;Pr&#233;valence du VIH&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevention-+" rel="tag"&gt;Pr&#233;vention&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prise-en-charge-+" rel="tag"&gt;Prise en charge&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Recherche-interventionnelle-+" rel="tag"&gt;Recherche interventionnelle&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Recherche-participative-+" rel="tag"&gt;Recherche participative/communautaire&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Recrutement-boules-de-neige-+" rel="tag"&gt;Recrutement &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;boules de neige&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Representations-Perceptions-+" rel="tag"&gt;Repr&#233;sentations / Perceptions&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Representativite-et-Biais-+" rel="tag"&gt;Repr&#233;sentativit&#233; et Biais&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Sante-publique-+" rel="tag"&gt;Sant&#233; publique&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Sante-sexuelle-+" rel="tag"&gt;Sant&#233; sexuelle&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Structure-des-populations-+" rel="tag"&gt;Structure des populations&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Structures-de-sante-+" rel="tag"&gt;Structures de sant&#233;&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Surveillance-sentinelle-+" rel="tag"&gt;Surveillance sentinelle&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Telephones-mobiles-+" rel="tag"&gt;T&#233;l&#233;phones mobiles&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Temporalites-142-+" rel="tag"&gt;Temporalit&#233;s&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Traitement-antiretroviral-ARV-98-98-+" rel="tag"&gt;Traitement antir&#233;troviral (ARV)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Travail-du-sexe-+" rel="tag"&gt;Travail du sexe&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Treatment-as-Prevention-TasP-105-+" rel="tag"&gt;Treatment as Prevention (TasP)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Universal-Test-Treat-UTT-+" rel="tag"&gt;Universal Test &amp; Treat (UTT)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Usagers-de-drogue-par-voie-+" rel="tag"&gt;Usager&lt;span aria-hidden='true'&gt;&#183;&lt;/span&gt;e&lt;span aria-hidden='true'&gt;&#183;&lt;/span&gt;s de drogue&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH109/ruban_spirales-a3fec.png?1715097926' class='spip_logo spip_logo_right' width='150' height='109' alt=&#034;&#034; /&gt;
		&lt;div class='rss_chapo'&gt;&lt;p&gt;Habilitation &#224; Diriger des Recherches soutenue le 12&#160;octobre 2012 par Joseph Larmarange &#224; l'Universit&#233; Paris Cit&#233;.&lt;/p&gt;&lt;/div&gt;
		&lt;div class='rss_texte'&gt;&lt;div class=&#034;hal-resultats&#034;&gt; &lt;div class=&#034;hal-resultat hal-resultat-3814024&#034;&gt; &lt;div class=&#034;hal-thumb&#034;&gt;&lt;a href=&#034;https://theses.hal.science/tel-03814024v1/document&#034; class=&#034;hal-thumb-link&#034;&gt;&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L53xH75/thumb-877a2ad2-17cac.png?1702907846' alt=&#034;Image document&#034; width='53' height='75' /&gt; &lt;/a&gt;&lt;/div&gt; &lt;div class=&#034;hal-preview&#034;&gt; &lt;a href=&#034;https://theses.hal.science/tel-03814024v1&#034; class=&#034;hal-titre&#034;&gt; &lt;h3 class=&#034;hal-titre-heading&#034;&gt;D&#233;crire les &#233;pid&#233;mies, Comprendre les populations : une d&#233;mographie du VIH en Afrique subsaharienne&lt;/h3&gt; &lt;/a&gt; &lt;div class=&#034;hal-auteurs&#034;&gt; &lt;a href=&#034;https://hal.science/search/index/q/*/authIdHal_s/joseph-larmarange&#034; class=&#034;hal-auteur&#034;&gt;Joseph Larmarange&lt;/a&gt; &lt;/div&gt; &lt;div class=&#034;hal-citation&#034;&gt;D&#233;mographie. Universit&#233; Paris Cit&#233;, 2022&lt;/div&gt; &lt;div class=&#034;hal-typedoc hal-typedoc-hdr&#034;&gt;HDR&lt;/div&gt; &lt;div class=&#034;hal-links&#034;&gt; &lt;a href=&#034;https://theses.hal.science/tel-03814024v1&#034; class=&#034;hal-link hal-link-hal&#034;&gt;tel-03814024&lt;/a&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;iframe width=&#034;100%&#034; height=&#034;500&#034; src=&#034;https://www.youtube.com/embed/me6rDSq0p0k&#034; title=&#034;YouTube video player&#034; frameborder=&#034;0&#034; allow=&#034;accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture&#034; allowfullscreen&gt;&lt;/iframe&gt;&lt;h2 class=&#034;spip&#034;&gt;
Jury&lt;/h2&gt;&lt;ul class=&#034;spip&#034; role=&#034;list&#034;&gt;&lt;li&gt; Didier Breton (Universit&#233; de Strasbourg, rapporteur)&lt;/li&gt;&lt;li&gt; Val&#233;rie Delauney (IRD, rapportrice)&lt;/li&gt;&lt;li&gt; Annabel Desgr&#233;es du Lo&#251; (IRD, garante)&lt;/li&gt;&lt;li&gt; G&#233;raldine Duth&#233; (Ined, rapportrice)&lt;/li&gt;&lt;li&gt; Didier Ekouevi (Inserm, Universit&#233; de Lom&#233;, examinateur)&lt;/li&gt;&lt;li&gt; V&#233;ronique Petit (Universit&#233; Paris Cit&#233;, pr&#233;sidente)&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
		
		</content:encoded>


		
		<enclosure url="https://www.joseph.larmarange.net/IMG/pdf/hdr_larmarange_v2022-10-12.pdf" length="15224200" type="application/pdf" />
		

	</item>
<item xml:lang="en">
		<title>What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?</title>
		<link>https://www.joseph.larmarange.net/What-do-the-Universal-Test-and</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/What-do-the-Universal-Test-and</guid>
		<dc:date>2020-02-25T09:49:53Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>en</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>Afrique subsaharienne</dc:subject>
		<dc:subject>TasP (ANRS 12249)</dc:subject>
		<dc:subject>Cascade des soins</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Incidence du VIH</dc:subject>
		<dc:subject>Mesure d'impact</dc:subject>
		<dc:subject>Sant&#233; publique</dc:subject>
		<dc:subject>Treatment as Prevention (TasP)</dc:subject>
		<dc:subject>Universal Test &amp; Treat (UTT)</dc:subject>
		<dc:subject>VIH / SIDA</dc:subject>

		<description>
&lt;p&gt;Authors Diane Havlir, Shahin Lockman, Helen Ayles, Joseph Larmarange, Gabriel Chamie, Tendani Gaolathe, Collins Iwuji, Sarah Fidler, Moses Kamya, Sian Floyd, Janet Moore, Richard Hayes, Maya Petersen, Francois Dabis on behalf of the (Universal Test and Treat Trials) UT3 Consortium &lt;br class='autobr' /&gt;
Abstract &lt;br class='autobr' /&gt;
Introduction &lt;br class='autobr' /&gt;
Achieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Publications-11-" rel="directory"&gt;Publications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-Afrique-subsaharienne-+" rel="tag"&gt;Afrique subsaharienne&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-TasP-ANRS-12249-97-+" rel="tag"&gt;TasP (ANRS 12249)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cascade-des-soins-+" rel="tag"&gt;Cascade des soins&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Incidence-du-VIH-+" rel="tag"&gt;Incidence du VIH&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Mesure-d-impact-+" rel="tag"&gt;Mesure d'impact&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Sante-publique-+" rel="tag"&gt;Sant&#233; publique&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Treatment-as-Prevention-TasP-105-+" rel="tag"&gt;Treatment as Prevention (TasP)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Universal-Test-Treat-UTT-+" rel="tag"&gt;Universal Test &amp; Treat (UTT)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH100/arton272-9bb2d.jpg?1715148445' class='spip_logo spip_logo_right' width='150' height='100' alt=&#034;&#034; /&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Authors&lt;/h2&gt;
&lt;p&gt;Diane Havlir, Shahin Lockman, Helen Ayles, Joseph Larmarange, Gabriel Chamie, Tendani Gaolathe, Collins Iwuji, Sarah Fidler, Moses Kamya, Sian Floyd, Janet Moore, Richard Hayes, Maya Petersen, Francois Dabis on behalf of the (Universal Test and Treat Trials) UT3 Consortium&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Abstract&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Achieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four randomized population&#8208;based trials (BCPP/Ya Tsie, HPTN 071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub&#8208;Saharan Africa (SSA) during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90&#8208;90&#8208;90 campaign.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Discussion&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;These three&#8208;year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a variety of home and community&#8208;based testing approaches) achieved &gt;90% coverage in all studies. (2) When coupled with robust linkage to HIV care, rapid ART start and patient&#8208;centred care, UTT achieved among the highest reported population levels of viral suppression in SSA. Significant gains in population&#8208;level viral suppression were made in regions with both low and high baseline population viral load; however, viral suppression gains were not uniform across all sub&#8208;populations and were lower among youth. (3) UTT resulted in marked reductions in community HIV incidence when universal testing and robust linkage were present. However, HIV elimination targets were not reached. In BCPP and HPTN 071, annualized HIV incidence was approximately 20% to 30% lower in the intervention (which included universal testing) compared to control arms (no universal testing). In SEARCH (where both arms had universal testing), incidence declined 32% over three years. (4) UTT reduced HIV associated mortality by 23% in the intervention versus control communities in SEARCH, a study in which mortality was comprehensively measured.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Conclusions&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;These trials provide strong evidence that UTT inclusive of universal testing increases population&#8208;level viral suppression and decreases HIV incidence and mortality faster than the status quo in SSA and should be adapted at a sub&#8208;country level as a public health strategy. However, more is needed, including integration of new prevention interventions into UTT, in order to reach UNAIDS HIV elimination targets.&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Reference&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;W2KH9JIL&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Havlir&lt;/span&gt; Diane, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Lockman&lt;/span&gt; Shahin, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Ayles&lt;/span&gt; Helen, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Chamie&lt;/span&gt; Gabriel, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Gaolathe&lt;/span&gt; Tendani, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Iwuji&lt;/span&gt; Collins, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Fidler&lt;/span&gt; Sarah, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Kamya&lt;/span&gt; Moses, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Floyd&lt;/span&gt; Sian, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Moore&lt;/span&gt; Janet, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Hayes&lt;/span&gt; Richard, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Petersen&lt;/span&gt; Maya and &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Dabis&lt;/span&gt; Francois (2020) &#8220;What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?&#8221;, &lt;span style=&#034;font-style: italic;&#034; &gt;Journal of the International AIDS Society&lt;/span&gt;, 23 (2) (February 24), p.&#160;e25455. DOI&#160;: 10.1002/jia2.25455. https://onlinelibrary.wiley.com/doi/abs/10.1002/jia2.25455.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>Cat&#233;gories &#233;pid&#233;miologiques, cat&#233;gories sociales et cat&#233;gories d'actions&#160;: doit-on repenser les &#171;&#160;populations cl&#233;s&#160;&#187; de la lutte contre le VIH&#160;?</title>
		<link>https://www.joseph.larmarange.net/Categories-epidemiologiques</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/Categories-epidemiologiques</guid>
		<dc:date>2020-01-22T13:00:00Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>Afrique subsaharienne</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Identit&#233;s sexuelles</dc:subject>
		<dc:subject>Mesure des indicateurs</dc:subject>
		<dc:subject>Homo / Bisexualit&#233;s</dc:subject>
		<dc:subject>Sant&#233; publique</dc:subject>
		<dc:subject>Structure des populations</dc:subject>
		<dc:subject>Travail du sexe</dc:subject>
		<dc:subject>VIH / SIDA</dc:subject>

		<description>
&lt;p&gt;Communication orale pr&#233;sent&#233;e &#224; la Conf&#233;rence Anthropo-Med &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;Dissonances et Convergences entre Anthropologie et Sant&#233; Publique&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187; le 22&#160;janvier 2020 &#224; Marseille &lt;br class='autobr' /&gt; R&#233;sum&#233; &lt;br class='autobr' /&gt;
Dans de nombreux pays, les populations cl&#233;s (en particulier les hommes ayant des rapports sexuels avec d'autres hommes, les professionnel(le)s du sexe et les consommateurs de drogues) sont massivement touch&#233;es par le VIH et de nombreux programmes se concentrent sur elles. En raison de la mod&#233;lisation &#233;pid&#233;miologique et de&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Communications-" rel="directory"&gt;Communications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-Afrique-subsaharienne-+" rel="tag"&gt;Afrique subsaharienne&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Identites-sexuelles-+" rel="tag"&gt;Identit&#233;s sexuelles&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Validite-de-la-mesure-+" rel="tag"&gt;Mesure des indicateurs&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-MSM-Homo-Bisexualite-+" rel="tag"&gt;Homo / Bisexualit&#233;s&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Sante-publique-+" rel="tag"&gt;Sant&#233; publique&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Structure-des-populations-+" rel="tag"&gt;Structure des populations&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Travail-du-sexe-+" rel="tag"&gt;Travail du sexe&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L120xH150/arton270-24817.jpg?1715152264' class='spip_logo spip_logo_right' width='120' height='150' alt=&#034;&#034; /&gt;
		&lt;div class='rss_chapo'&gt;&lt;p&gt;Communication orale pr&#233;sent&#233;e &#224; la Conf&#233;rence &lt;i&gt;Anthropo-Med &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;Dissonances et Convergences entre Anthropologie et Sant&#233; Publique&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;&lt;/i&gt; le 22&#160;janvier 2020 &#224; Marseille&lt;/p&gt;&lt;/div&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
R&#233;sum&#233;&lt;/h2&gt;
&lt;p&gt;Dans de nombreux pays, les populations cl&#233;s (en particulier les hommes ayant des rapports sexuels avec d'autres hommes, les professionnel(le)s du sexe et les consommateurs de drogues) sont massivement touch&#233;es par le VIH et de nombreux programmes se concentrent sur elles. En raison de la mod&#233;lisation &#233;pid&#233;miologique et de la planification des politiques, ces groupes sont trop souvent consid&#233;r&#233;s comme des groupes socialement homog&#232;nes plut&#244;t que des cat&#233;gories h&#233;t&#233;rog&#232;nes aux contours flous. Les identit&#233;s, la vie sociale, les pratiques sexuelles, l'exposition au VIH varient au sein de ces groupes, en particulier entre le noyau et les p&#233;riph&#233;riques. Leurs r&#233;seaux sexuels sont &#233;galement interconnect&#233;s avec des personnes qui ne sont pas per&#231;ues comme appartenant &#224; ces &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;populations cl&#233;s&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;&#160;: partenaires f&#233;minines d'hommes bisexuels, partenaires r&#233;guliers et clients de professionnel(le)s du sexe, partenaires sexuels de consommateurs de drogues...&lt;/p&gt;
&lt;p&gt;Entre les cat&#233;gories &#233;pid&#233;miologiques, les cat&#233;gories sociales et identitaires et les cat&#233;gories d'actions, comment pouvons-nous appr&#233;hender la diversit&#233; des populations cl&#233;s&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;? La notion de populations p&#233;riph&#233;riques peut-elle faire sens&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;? Quel est le r&#244;le de ces populations p&#233;riph&#233;riques dans la dynamique des populations cl&#233;s et comment les prendre en compte dans la riposte au VIH&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;?&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
R&#233;f&#233;rence&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;YVYM79SG&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph (2020) &#8220;Cat&#233;gories &#233;pid&#233;miologiques, cat&#233;gories sociales et cat&#233;gories d'actions : doit-on repenser les &#034;populations cl&#233;s&#034; de la lutte contre le VIH ?&#8221; (communication orale), presented at the &lt;span style=&#034;font-style: italic;&#034; &gt;Conf&#233;rence Anthropo-Med &#034;Dissonances et Convergences entre Anthropologie et Sant&#233; Publique&#034;&lt;/span&gt;, Marseille. https://imera.univ-amu.fr/fr/conference-anthropo-med-dissonances-convergences-entre-anthropologie-sante-publique.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		
		<enclosure url="https://www.joseph.larmarange.net/IMG/pdf/larmarange_anthropomed_v2020-01-22.pdf" length="2280080" type="application/pdf" />
		

	</item>
<item xml:lang="en">
		<title>Female sex workers and HIV acquisition in C&#244;te d'Ivoire: the burden of precariousness and working conditions (ANRS 12361 PREP-CI)</title>
		<link>https://www.joseph.larmarange.net/Female-sex-workers-and-HIV</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/Female-sex-workers-and-HIV</guid>
		<dc:date>2019-05-17T05:00:00Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>en</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>VIH / SIDA</dc:subject>
		<dc:subject>Pr&#233;vention</dc:subject>
		<dc:subject>Pauvret&#233;</dc:subject>
		<dc:subject>C&#244;te d'Ivoire</dc:subject>
		<dc:subject>In&#233;galit&#233;s de genre</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Travail du sexe</dc:subject>
		<dc:subject>PrEP CI (ANRS 12361)</dc:subject>
		<dc:subject>Sant&#233; sexuelle</dc:subject>
		<dc:subject>Incidence du VIH</dc:subject>

		<description>
&lt;p&gt;Oral presentation of a poster at the 2019 INTEREST Workshop, the 17&lt;sup class=&#034;typo_exposants&#034;&gt;th&lt;/sup&gt; of May, 2019, Accra, Ghana. &lt;br class='autobr' /&gt; Authors &lt;br class='autobr' /&gt;
N'zebo Marcellin Nouaman, Valentine Becquet, Jean-Marie Masumbuko, Camille Anoma, Kouam&#233; Soh, M&#233;lanie Plazy, Christine Danel, Serge Eholi&#233; and Joseph Larmarange &lt;br class='autobr' /&gt;
Abstract &lt;br class='autobr' /&gt;
Background Female sex workers (FSW) are a population at high risk of HIV acquisition. New tools to diagnose recent HIV infection may be used to better describe risk of HIV acquisition in this group. The ANRS&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Communications-" rel="directory"&gt;Communications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevention-+" rel="tag"&gt;Pr&#233;vention&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Pauvrete-+" rel="tag"&gt;Pauvret&#233;&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cote-d-Ivoire-+" rel="tag"&gt;C&#244;te d'Ivoire&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Inegalites-de-genre-+" rel="tag"&gt;In&#233;galit&#233;s de genre&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Travail-du-sexe-+" rel="tag"&gt;Travail du sexe&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PrEP-CI-ANRS-12361-+" rel="tag"&gt;PrEP CI (ANRS 12361)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Sante-sexuelle-+" rel="tag"&gt;Sant&#233; sexuelle&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Incidence-du-VIH-+" rel="tag"&gt;Incidence du VIH&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH102/arton248-05adc.jpg?1715130051' class='spip_logo spip_logo_right' width='150' height='102' alt=&#034;&#034; /&gt;
		&lt;div class='rss_chapo'&gt;&lt;p&gt;Oral presentation of a poster at the &lt;a href=&#034;http://interestworkshop.org/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;2019 INTEREST Workshop&lt;/a&gt;, the 17&lt;sup class=&#034;typo_exposants&#034;&gt;th&lt;/sup&gt; of May, 2019, Accra, Ghana.&lt;/p&gt;&lt;/div&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Authors&lt;/h2&gt;
&lt;p&gt;N'zebo Marcellin Nouaman, Valentine Becquet, Jean-Marie Masumbuko, Camille Anoma, Kouam&#233; Soh, M&#233;lanie Plazy, Christine Danel, Serge Eholi&#233; and Joseph Larmarange&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Abstract&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;Background&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Female sex workers (FSW) are a population at high risk of HIV acquisition. New tools to diagnose recent HIV infection may be used to better describe risk of HIV acquisition in this group. The ANRS 12361 PrEP-CI project aimed to estimate HIV incidence and describe risk factors among FSW in C&#244;te d'Ivoire.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Methods&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The study was conducted between September 2016 and March 2017 among FSW aged &#8805;18 years old in Abidjan and San Pedro. Two rapid tests for recent HIV infection (Determine&#174;, Alere and Vikia&#174;, bio M&#233;rieux) were offered to FSW; in case of positive result, a dried blood sport was collected and window period of infection determined using a test for recent infection (EIA-RI) adapted to the Ivorian context. A standardized sociodemographic questionnaire was then administered to FSW by female peer educators, completed with qualitative interviews and focus groups with 60 FSW.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Results&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;1000 SW (400 in San Pedro and 600 in Abidjan) with a median age of 25 years (interquartile range: 21-29) were included in the study and screened for HIV. Of these, 39 were diagnosed with HIV, 7 of which were newly infected (mean duration of infection was 113 days), corresponding to an HIV incidence of 2.3% [95% confidence interval: 1.6 - 3.1%]. The incidence was higher in San Pedro (3.3% [2.2-4.5]) than in Abidjan (1.6% [1.1-2.2]); this can be explained by qualitative data in which FSW in San Pedro expressed difficulties (distance, time, costs ...) in accessing health care services and prevention methods, particularly regarding condoms. HIV infection was also associated with vulnerability: the incidence was higher among those who charged &#8804; 2000 CFA francs per intercourse (3.3% vs. 0.7%), those who performed on the streets or in hotels (5.4% and 4.2%, respectively, vs. 3.9% in brothel and 0.8% in bar &#8211; drinking spot), and among those who had more than 5 clients the last working day (6.1% vs. 1.8% among those who had under 5 clients) and who could be more difficult to identify and refer to HIV prevention services by female peer educators. Finally, FSW under &lt;25 years old were at higher risk of infection (2.8%) than older ones (1.8%), and HIV incidence was associated with other sexually transmitted infections (STI) (2.5% in those who had &#8805; 1 STI in the last 12 months vs. 1.9%). Contrary to expectations, an extensive sex work experience did not reduce exposure to HIV, when we compared FSW who had been working for more than 3 years with the ones who had newly arrived in the sex work industry (2.5% vs. 2.0%).&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Conclusion&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;This study is one of the first to estimate HIV incidence in C&#244;te d'Ivoire among FSW. This key population is much more exposed than the rest of the general population (2.3% vs. 0.06% estimated by UNAIDS). New infections seem to concentrated among younger FSW in precarious situations and working in remote areas, such as San Pedro area. These vulnerable subgroups should therefore be a priority target for prevention programs such as pre-exposure prophylaxis (PrEP) as recommended by WHO.&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Reference&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;JL27FEV8&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Nouaman&lt;/span&gt; Marcellin, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Becquet&lt;/span&gt; Valentine, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Masumbuko&lt;/span&gt; Jean-Marie, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Anoma&lt;/span&gt; Camille, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Soh&lt;/span&gt; Kouam&#233;, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Plazy&lt;/span&gt; M&#233;lanie, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Danel&lt;/span&gt; Christine, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Eholi&#233;&lt;/span&gt; Serge and &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph (2019) &#8220;Female sex workers and HIV acquisition in C&#244;te d'Ivoire: the burden of precariousness and working conditions (ANRS 12361 PREP-CI)&#8221; (poster discussion), presented at the &lt;span style=&#034;font-style: italic;&#034; &gt;INTEREST Workshop&lt;/span&gt;, Accra.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>D&#233;pister, traiter les populations cach&#233;es</title>
		<link>https://www.joseph.larmarange.net/Depister-traiter-les-populations</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/Depister-traiter-les-populations</guid>
		<dc:date>2018-04-08T16:16:43Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>VIH / SIDA</dc:subject>
		<dc:subject>Homo / Bisexualit&#233;s</dc:subject>
		<dc:subject>Pr&#233;vention</dc:subject>
		<dc:subject>Afrique subsaharienne</dc:subject>
		<dc:subject>Identit&#233;s sexuelles</dc:subject>
		<dc:subject>Recrutement &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;boules de neige&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;</dc:subject>
		<dc:subject>Acc&#232;s aux soins</dc:subject>
		<dc:subject>Repr&#233;sentativit&#233; et Biais</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Traitement antir&#233;troviral (ARV)</dc:subject>
		<dc:subject>D&#233;pistage</dc:subject>
		<dc:subject>Prise en charge</dc:subject>
		<dc:subject>Travail du sexe</dc:subject>
		<dc:subject>Treatment as Prevention (TasP)</dc:subject>

		<description>
&lt;p&gt;Communication orale pr&#233;sent&#233;e en session pl&#233;ni&#232;re le 5&#160;avril 2018 lors de la 9&lt;sup class=&#034;typo_exposants&#034;&gt;e&lt;/sup&gt; conf&#233;rence francophone sur le VIH et les h&#233;patites virales &#224; Bordeaux. Auteur &lt;br class='autobr' /&gt;
Joseph Larmarange Vid&#233;o Pr&#233;sentation Pl&#233;ni&#232;re AFRAVIH 2018 (Joseph Larmarange)3.1&#160;Mio R&#233;f&#233;rence &lt;br class='autobr' /&gt;
Larmarange Joseph (2018) &#8220;D&#233;pister, traiter les populations cach&#233;es&#8221; (communication orale en session pl&#233;ni&#232;re), presented at the 9&lt;sup class=&#034;typo_exposants&#034;&gt;e&lt;/sup&gt; Conf&#233;rence Internationale Francophone sur le VIH et les H&#233;patites Virales (AFRAVIH 2018), Bordeaux.&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Communications-" rel="directory"&gt;Communications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-MSM-Homo-Bisexualite-+" rel="tag"&gt;Homo / Bisexualit&#233;s&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevention-+" rel="tag"&gt;Pr&#233;vention&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Afrique-subsaharienne-+" rel="tag"&gt;Afrique subsaharienne&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Identites-sexuelles-+" rel="tag"&gt;Identit&#233;s sexuelles&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Recrutement-boules-de-neige-+" rel="tag"&gt;Recrutement &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;boules de neige&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Acces-aux-soins-+" rel="tag"&gt;Acc&#232;s aux soins&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Representativite-et-Biais-+" rel="tag"&gt;Repr&#233;sentativit&#233; et Biais&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Traitement-antiretroviral-ARV-98-98-+" rel="tag"&gt;Traitement antir&#233;troviral (ARV)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Depistage-+" rel="tag"&gt;D&#233;pistage&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prise-en-charge-+" rel="tag"&gt;Prise en charge&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Travail-du-sexe-+" rel="tag"&gt;Travail du sexe&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Treatment-as-Prevention-TasP-105-+" rel="tag"&gt;Treatment as Prevention (TasP)&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH84/arton230-4237a.jpg?1715174926' class='spip_logo spip_logo_right' width='150' height='84' alt=&#034;&#034; /&gt;
		&lt;div class='rss_chapo'&gt;&lt;p&gt;Communication orale pr&#233;sent&#233;e en session pl&#233;ni&#232;re le 5&#160;avril 2018 lors de la &lt;a href=&#034;http://www.afravih2018.org/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;9&lt;sup&gt;e&lt;/sup&gt; conf&#233;rence francophone sur le VIH et les h&#233;patites virales&lt;/a&gt; &#224; Bordeaux.&lt;/p&gt;&lt;/div&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Auteur&lt;/h2&gt;
&lt;p&gt;Joseph Larmarange&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Vid&#233;o&lt;/h2&gt;&lt;iframe width=&#034;100%&#034; height=&#034;400&#034; src=&#034;https://www.youtube-nocookie.com/embed/SdBcT2dPgl4?showinfo=0&amp;start=48&#034; frameborder=&#034;0&#034; allow=&#034;autoplay; encrypted-media&#034; allowfullscreen style=&#034;max-width:100%;&#034;&gt;&lt;/iframe&gt;&lt;dl class='spip_document_238 spip_documents spip_documents_center media media_logo'&gt; &lt;dt&gt;&lt;a href='https://www.joseph.larmarange.net/IMG/pdf/afravih_2018_pleniere_larmarange.pdf' class=&#034;spip_in&#034; title=&#034;Pr&#233;sentation Pl&#233;ni&#232;re AFRAVIH 2018 (Joseph Larmarange)&#034; hreflang=&#034;&#034; type=&#034;application/pdf&#034;&gt;&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L64xH64/pdf-b8aed.svg?1772799023' height='64' width='64' alt='Pr&#233;sentation Pl&#233;ni&#232;re AFRAVIH 2018 (Joseph Larmarange)' /&gt;&lt;/a&gt;&lt;/dt&gt; &lt;dt class='spip_doc_titre crayon document-titre-238' style='max-width: 350px;'&gt;&lt;strong&gt;Pr&#233;sentation Pl&#233;ni&#232;re AFRAVIH 2018 (Joseph Larmarange)&lt;/strong&gt;&lt;/dt&gt;&lt;dd class='spip_doc_infos' style='max-width: 350px;'&gt;3.1&#160;Mio&lt;/dd&gt;&lt;/dl&gt;&lt;h2 class=&#034;spip&#034;&gt;
R&#233;f&#233;rence&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;BEVZD6WQ&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph (2018) &#8220;D&#233;pister, traiter les populations cach&#233;es&#8221; (communication orale en session pl&#233;ni&#232;re), presented at the &lt;span style=&#034;font-style: italic;&#034; &gt;9e Conf&#233;rence Internationale Francophone sur le VIH et les H&#233;patites Virales (AFRAVIH 2018)&lt;/span&gt;, Bordeaux. https://www.youtube.com/watch?time_continue=48&amp;v=SdBcT2dPgl4.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>&#201;valuation de l'incidence du VIH chez des travailleuses du sexe en C&#244;te d'Ivoire (PREPCI ANRS 12361)</title>
		<link>https://www.joseph.larmarange.net/Evaluation-de-l-incidence-du-VIH</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/Evaluation-de-l-incidence-du-VIH</guid>
		<dc:date>2018-04-08T15:45:01Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>VIH / SIDA</dc:subject>
		<dc:subject>Pr&#233;vention</dc:subject>
		<dc:subject>C&#244;te d'Ivoire</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Travail du sexe</dc:subject>
		<dc:subject>PrEP</dc:subject>
		<dc:subject>PrEP CI (ANRS 12361)</dc:subject>
		<dc:subject>Incidence du VIH</dc:subject>

		<description>
&lt;p&gt;Communication orale pr&#233;sent&#233;e le 5&#160;avril 2018 lors de la 9&lt;sup class=&#034;typo_exposants&#034;&gt;e&lt;/sup&gt; conf&#233;rence francophone sur le VIH et les h&#233;patites virales &#224; Bordeaux. &lt;br class='autobr' /&gt; Auteurs &lt;br class='autobr' /&gt;
N'zebo Marcellin Nouaman, Valentine Becquet, Jean-Marie Masumbuko, Camille Anoma, Kouam&#233; Soh, M&#233;lanie Plazy, Christine Danel, Serge Eholi&#233;, Joseph Larmarange &lt;br class='autobr' /&gt;
Vid&#233;o&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Communications-" rel="directory"&gt;Communications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevention-+" rel="tag"&gt;Pr&#233;vention&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cote-d-Ivoire-+" rel="tag"&gt;C&#244;te d'Ivoire&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Travail-du-sexe-+" rel="tag"&gt;Travail du sexe&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PrEP-+" rel="tag"&gt;PrEP&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PrEP-CI-ANRS-12361-+" rel="tag"&gt;PrEP CI (ANRS 12361)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Incidence-du-VIH-+" rel="tag"&gt;Incidence du VIH&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH75/arton226-08fd5.jpg?1715174700' class='spip_logo spip_logo_right' width='150' height='75' alt=&#034;&#034; /&gt;
		&lt;div class='rss_chapo'&gt;&lt;p&gt;Communication orale pr&#233;sent&#233;e le 5&#160;avril 2018 lors de la &lt;a href=&#034;http://www.afravih2018.org/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;9&lt;sup&gt;e&lt;/sup&gt; conf&#233;rence francophone sur le VIH et les h&#233;patites virales&lt;/a&gt; &#224; Bordeaux.&lt;/p&gt;&lt;/div&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Auteurs&lt;/h2&gt;
&lt;p&gt;N'zebo Marcellin Nouaman, Valentine Becquet, Jean-Marie Masumbuko, Camille Anoma, Kouam&#233; Soh, M&#233;lanie Plazy, Christine Danel, Serge Eholi&#233;, Joseph Larmarange&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Vid&#233;o&lt;/h2&gt;&lt;div class=&#034;spip_document_ spip_document spip_documents spip_document_video ressource oembed oembed_video oembed_video oembed_youtube&#034; &gt; &lt;figure class=&#034;spip_doc_inner&#034;&gt; &lt;div class=&#034;oembed oe-video async clearfix&#034; style=&#034;max-width:800px;&#034;&gt; &lt;div class=&#034;rwd-video-container oe-play-button&#034; style=&#034;width:100%;height:0;padding-bottom:56.25%;background-image:url('https://i.ytimg.com/vi/P4_Albn2IRI/hqdefault.jpg');background-repeat:no-repeat;background-position:center;background-size:cover;&#034; data-content=&#034;%3Ciframe%20width%3D%22800%22%20height%3D%22450%22%20src%3D%22https%3A%2F%2Fwww.youtube-nocookie.com%2Fembed%2FP4_Albn2IRI%3Ffeature%3Doembed%26autoplay%3D1%22%20frameborder%3D%220%22%20allow%3D%22accelerometer%3B%20autoplay%3B%20clipboard-write%3B%20encrypted-media%3B%20gyroscope%3B%20picture-in-picture%3B%20web-share%22%20referrerpolicy%3D%22strict-origin-when-cross-origin%22%20allowfullscreen%20title%3D%22S6%20-%20Populations%20cl%C3%A9s%20-%20%C3%89valuation%20de%20l%E2%80%99incidence%20du%20VIH%20chez%20des%20travailleuses%20du%20sexe...%22%3E%3C%2Fiframe%3E&#034;&gt; &lt;button&gt;&lt;span class=&#034;oe-play-button_label&#034;&gt;Lecture&lt;/span&gt;&lt;/button&gt; &lt;/div&gt; &lt;style&gt;&lt;!--/**/.oe-video .loading {background-image:url(&#034;prive/themes/spip/images/searching.gif&#034;)!important;background-size:auto !important;}/**/--&gt;&lt;/style&gt;
&lt;/div&gt; &lt;figcaption class=&#034;spip_doc_legende&#034;&gt;
&lt;div class=&#034;spip_doc_titre&#034; style=&#034;max-width:800px;&#034;&gt;&lt;a href=&#034;https://www.youtube.com/watch?v=P4_Albn2IRI&#034; class=&#034;oe-title&#034;&gt;S6 - Populations cl&#233;s - &#201;valuation de l'incidence du VIH chez des travailleuses du sexe...&lt;/a&gt; &lt;span class=&#034;oe-author&#034;&gt;&lt;br/&gt;&lt;span class=&#034;oe-author_par&#034;&gt;par &lt;/span&gt;&lt;a href=&#034;https://www.youtube.com/@AFRAVIH&#034; class=&#034;oe-author_name&#034;&gt;AFRAVIH 2018&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&#034;spip_doc_titre oembed-source&#034;&gt;&lt;a href=&#034;https://www.youtube.com/watch?v=P4_Albn2IRI&#034; class=&#034;spip_url spip_out auto&#034; rel=&#034;nofollow external&#034;&gt;https://www.youtube.com/watch?v=P4_Albn2IRI&lt;/a&gt;&lt;/div&gt;
&lt;/figcaption&gt; &lt;div class=&#034;base64javascript200413011969de84ea646a64.07161439&#034; title=&#034;PHNjcmlwdD5qUXVlcnkoZnVuY3Rpb24oKXsgalF1ZXJ5KCcub2VtYmVkLm9lLXZpZGVvLmFzeW5jJykubm90KCcuZG9uZScpLmFkZENsYXNzKCdkb25lJykub24oJ2NsaWNrJywgJy5vZS1wbGF5LWJ1dHRvbicsZnVuY3Rpb24oZSl7dmFyICRtZSA9IGpRdWVyeSh0aGlzKSxjb250ZW50ID0gZGVjb2RlVVJJQ29tcG9uZW50KCRtZS5kYXRhKCdjb250ZW50JykpOyRtZS5yZW1vdmVDbGFzcygnb2UtcGxheS1idXR0b24nKS5hZGRDbGFzcygnbG9hZGluZycpLmh0bWwoY29udGVudCk7fSl9KTwvc2NyaXB0Pg==&#034;&gt;&lt;/div&gt; &lt;/figure&gt;
&lt;/div&gt;&lt;h2 class=&#034;spip&#034;&gt;
R&#233;sum&#233;&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;Contexte&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Bien que les travailleuses du sexe (TS) constituent une population particuli&#232;rement &#224; risque du VIH, la compr&#233;hension du fardeau du VIH reste limit&#233;e dans cette population en Afrique subsaharienne. Le projet PrEP-CI ANRS 12361 comportait une estimation de l'incidence de l'infection VIH chez des TS en C&#244;te d'Ivoire &#224; l'aide de tests d'infection r&#233;cente.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;M&#233;thodes&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;L'&#233;tude a &#233;t&#233; conduite entre septembre 2016 et mars 2017 aupr&#232;s de TS &#226;g&#233;es de 18 ans et plus &#224; Abidjan et &#224; San Pedro, en mobilisant une m&#233;thodologie mixte&#160;:(i) des entretiens qualitatifs individuels et des focus groupes aupr&#232;s de 60 TS,(ii) un questionnaire sociod&#233;mographique standardis&#233; ainsi qu'un d&#233;pistage du VIH par deux tests rapides (Determine&#174;, Alere et Vikia&#174;, bio M&#233;rieux) administr&#233;s par des paires &#233;ducatrices sur les sites prostitutionnels aupr&#232;s de 1000 TS. En cas de positivit&#233;, un pr&#233;l&#232;vement sur DBS a &#233;t&#233; r&#233;alis&#233; pour d&#233;terminer la fen&#234;tre d'infection &#224; l'aide d'un test d'infection r&#233;cente (EIA-RI) adapt&#233; au contexte ivoirien.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;R&#233;sultats&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;1000 TS (400 &#224; San Pedro, 600 &#224; Abidjan) avec un &#226;ge m&#233;dian de 25 ans [Intervalle Interquartile = 21-29] ont &#233;t&#233; incluses dans l'&#233;tude et ont &#233;t&#233; d&#233;pist&#233;es pour le VIH. Parmi elles, 39 ont &#233;t&#233; diagnostiqu&#233;es VIH+, dont 7 infect&#233;es r&#233;cemment (dur&#233;e moyenne de la dur&#233;e d'infection de 113 jours), correspondant &#224; une incidence du VIH de 2,2%.&lt;/p&gt;
&lt;p&gt;L'incidence est plus &#233;lev&#233;e &#224; San Pedro (3,2%) qu'&#224; Abidjan (1,5%). Ces r&#233;sultats sont &#224; mettre en regard des donn&#233;es qualitatives&#160;: les TS de San Pedro ont t&#233;moign&#233; de difficult&#233;s (distance, horaires, co&#251;ts &#8230;) &#224; acc&#233;der aux soins de sant&#233; et aux moyens de pr&#233;vention, notamment le pr&#233;servatif. L'infection &#224; VIH est &#233;galement associ&#233;e &#224; la vuln&#233;rabilit&#233;&#160;: l'incidence est plus &#233;lev&#233;e chez celles qui pratiquent des passes &#8804; 2000 CFA (3,1% vs. 0,7%)&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; chez celles qui exercent sur les trottoirs (5,1%) et dans les h&#244;tels (3,8%)&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; et chez celles qui ne travaillent qu'une fois par semaine (2,9% vs. 0 cas incident observ&#233; chez celles qui travaillent tous les jours). Les TS travaillant occasionnellement sont plus difficilement identifi&#233;es par les paires &#233;ducatrices et ont moins acc&#232;s &#224; la pr&#233;vention. Enfin, les TS de moins de 25 ans sont plus &#224; risque d'infection (2,6%) que celles de plus &#226;g&#233;es (1,6%) et l'incidence du VIH est associ&#233;e aux autres IST (2,3% chez celles ayant eu &#8805;1 IST au cours des 12 derniers mois vs 1,8%).&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Conclusion&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Cette &#233;tude est l'une des premi&#232;res &#224; estimer l'incidence du VIH en C&#244;te d'Ivoire chez les TS. Cette population est beaucoup plus expos&#233;e que le reste de la population g&#233;n&#233;rale (2,2% vs. 0,06% estim&#233; par l'Onusida). Les nouvelles infections se concentrent chez les TS plus jeunes, en situation pr&#233;caire et travaillant dans des zones recul&#233;es, en particulier dans la r&#233;gion de San Pedro. Ces sous-groupes vuln&#233;rables doivent donc &#234;tre vis&#233;s en priorit&#233; par les programmes de pr&#233;vention et devraient se voir proposer une prophylaxie pr&#233;exposition (PrEP) selon les recommandations de l'OMS.&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
R&#233;f&#233;rence&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;EE8UFFWB&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Nouaman&lt;/span&gt; Marcellin, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Becquet&lt;/span&gt; Valentine, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Masumbuko&lt;/span&gt; Jean-Marie, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Anoma&lt;/span&gt; Camille, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Soh&lt;/span&gt; Kouam&#233;, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Plazy&lt;/span&gt; M&#233;lanie, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Danel&lt;/span&gt; Christine, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Eholi&#233;&lt;/span&gt; Serge and &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph (2018) &#8220;&#201;valuation de l'incidence du VIH chez des travailleuses du sexe en C&#244;te d'Ivoire (PREPCI ANRS 12361)&#8221; (communication orale S6.04), presented at the &lt;span style=&#034;font-style: italic;&#034; &gt;9e Conf&#233;rence Internationale Francophone sur le VIH et les H&#233;patites Virales (AFRAVIH 2018)&lt;/span&gt;, Bordeaux.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>RIPOST &#8226; R&#233;seau des Instituts Nationaux de Sant&#233; Publique d'Afrique de l'Ouest</title>
		<link>https://www.joseph.larmarange.net/RIPOST-o-Reseau-des-Instituts</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/RIPOST-o-Reseau-des-Instituts</guid>
		<dc:date>2018-01-07T19:38:20Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>M&#233;thodologie</dc:subject>
		<dc:subject>Surveillance sentinelle</dc:subject>
		<dc:subject>Burkina Faso</dc:subject>
		<dc:subject>Guin&#233;e</dc:subject>
		<dc:subject>C&#244;te d'Ivoire</dc:subject>
		<dc:subject>B&#233;nin</dc:subject>
		<dc:subject>Niger</dc:subject>
		<dc:subject>Togo</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>T&#233;l&#233;phones mobiles</dc:subject>
		<dc:subject>RIPOST</dc:subject>
		<dc:subject>Sant&#233; publique</dc:subject>

		<description>
&lt;p&gt;Partenariat AMP ISPED Sant&#233; Publique France IANPHI IRD Solthis &lt;br class='autobr' /&gt;
Financement Agence Fran&#231;aise de D&#233;veloppement (AFD) &lt;br class='autobr' /&gt;
R&#233;sum&#233; &lt;br class='autobr' /&gt;
L'&#233;pid&#233;mie d'Ebola qui a s&#233;vi en Afrique de l'Ouest en 2014-2015 a r&#233;v&#233;l&#233; un certain nombre de faiblesses dans les dispositifs de veille, d'alerte, d'investigation, de r&#233;ponse rapide et plus g&#233;n&#233;ralement des syst&#232;mes d'information en sant&#233; au niveau national et international. &lt;br class='autobr' /&gt;
Le projet d&#233;pos&#233; en consortium a pour chef de file l'AMP&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; et ADERA-ISPED, Sant&#233; Publique&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Projets-de-Recherche-" rel="directory"&gt;Projets de Recherche&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-Methodologie-+" rel="tag"&gt;M&#233;thodologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Surveillance-sentinelle-+" rel="tag"&gt;Surveillance sentinelle&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Burkina-Faso-+" rel="tag"&gt;Burkina Faso&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Guinee-+" rel="tag"&gt;Guin&#233;e&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cote-d-Ivoire-+" rel="tag"&gt;C&#244;te d'Ivoire&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Benin-+" rel="tag"&gt;B&#233;nin&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Niger-+" rel="tag"&gt;Niger&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Togo-+" rel="tag"&gt;Togo&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Telephones-mobiles-+" rel="tag"&gt;T&#233;l&#233;phones mobiles&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-RIPOST-+" rel="tag"&gt;RIPOST&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Sante-publique-+" rel="tag"&gt;Sant&#233; publique&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH100/arton222-a94ad.jpg?1715148300' class='spip_logo spip_logo_right' width='150' height='100' alt=&#034;&#034; /&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Partenariat&lt;/h2&gt;&lt;ul class=&#034;spip&#034; role=&#034;list&#034;&gt;&lt;li&gt; &lt;a href=&#034;http://amp-vaccinology.org/fr&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;AMP&lt;/a&gt;&lt;/li&gt;&lt;li&gt; &lt;a href=&#034;http://www.isped.u-bordeaux.fr/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;ISPED&lt;/a&gt;&lt;/li&gt;&lt;li&gt; &lt;a href=&#034;https://www.santepubliquefrance.fr/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;Sant&#233; Publique France&lt;/a&gt;&lt;/li&gt;&lt;li&gt; &lt;a href=&#034;http://www.ianphi.org/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;IANPHI&lt;/a&gt;&lt;/li&gt;&lt;li&gt; &lt;a href=&#034;http://www.ird.fr&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;IRD&lt;/a&gt;&lt;/li&gt;&lt;li&gt; &lt;a href=&#034;https://www.solthis.org/&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;Solthis&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h2 class=&#034;spip&#034;&gt;
Financement&lt;/h2&gt;&lt;ul class=&#034;spip&#034; role=&#034;list&#034;&gt;&lt;li&gt; &lt;a href=&#034;https://www.afd.fr&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;Agence Fran&#231;aise de D&#233;veloppement (AFD)&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h2 class=&#034;spip&#034;&gt;
R&#233;sum&#233;&lt;/h2&gt;
&lt;p&gt;L'&#233;pid&#233;mie d'Ebola qui a s&#233;vi en Afrique de l'Ouest en 2014-2015 a r&#233;v&#233;l&#233; un certain nombre de faiblesses dans les dispositifs de veille, d'alerte, d'investigation, de r&#233;ponse rapide et plus g&#233;n&#233;ralement des syst&#232;mes d'information en sant&#233; au niveau national et international.&lt;/p&gt;
&lt;p&gt;Le projet d&#233;pos&#233; en consortium a pour chef de file l'AMP&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; et ADERA-ISPED, Sant&#233; Publique France, IANPHI, IRD et Solthis pour membres. Ce projet cible 6 pays&#160;: B&#233;nin, Burkina Faso, C&#244;te d'Ivoire, Guin&#233;e, Niger et Togo pour l'axe consacr&#233; au renforcement des capacit&#233;s en &#233;pid&#233;miologie et la C&#244;te d'Ivoire et la Guin&#233;e pour l'axe consacr&#233; &#224; la mobilisation communautaire.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Axe renforcement des capacit&#233;s&#160;:&lt;/strong&gt;&lt;/p&gt;
&lt;ul class=&#034;spip&#034; role=&#034;list&#034;&gt;&lt;li&gt; Les responsables des institutions nationales de sant&#233; publique et de coordination nationale de la surveillance de la riposte&lt;/li&gt;&lt;li&gt; Les r&#233;f&#233;rents en mati&#232;re de surveillance, investigation et syst&#232;mes d'information dans les r&#233;gions et district sanitaires&lt;/li&gt;&lt;li&gt; Tout professionnel de sant&#233; publique (m&#233;decin, v&#233;t&#233;rinaire, pharmacien param&#233;dical et ing&#233;nieur sanitaire), dont l'activit&#233; est ax&#233;e sur la pratique de l'&#233;pid&#233;miologie au niveau national et r&#233;gional&lt;/li&gt;&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;Axe mobilisation communautaire&#160;:&lt;/strong&gt;&lt;/p&gt;
&lt;ul class=&#034;spip&#034; role=&#034;list&#034;&gt;&lt;li&gt; Les experts et institutions nationales de sant&#233; publique pour la mise en &#339;uvre, le suivi et l'analyse des enqu&#234;tes &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;Barom&#232;tre Sant&#233;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;&lt;/li&gt;&lt;li&gt; Les r&#233;f&#233;rents en mati&#232;re de surveillance, investigation et syst&#232;mes d'information dans les r&#233;gions et districts sanitaires&lt;/li&gt;&lt;li&gt; Les informateurs communautaires cl&#233;s pour l'accompagnement d'un dispositif de surveillance communautaire&lt;/li&gt;&lt;/ul&gt;&lt;h2 class=&#034;spip&#034;&gt;
Zone g&#233;ographique&lt;/h2&gt;
&lt;p&gt;B&#233;nin, Burkina Faso, C&#244;t&#233; d'Ivoire, Guin&#233;e, Niger et Togo&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Calendrier&lt;/h2&gt;
&lt;p&gt;2017-2021&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>La fin du sida est-elle en vue&#160;?</title>
		<link>https://www.joseph.larmarange.net/La-fin-du-sida-est-elle-en-vue</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/La-fin-du-sida-est-elle-en-vue</guid>
		<dc:date>2017-06-29T09:12:43Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>VIH / SIDA</dc:subject>
		<dc:subject>Pr&#233;vention</dc:subject>
		<dc:subject>Mod&#233;lisation</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>Traitement antir&#233;troviral (ARV)</dc:subject>
		<dc:subject>Treatment as Prevention (TasP)</dc:subject>
		<dc:subject>Cascade des soins</dc:subject>
		<dc:subject>Universal Test &amp; Treat (UTT)</dc:subject>
		<dc:subject>PrEP</dc:subject>

		<description>
&lt;p&gt;Auteurs &lt;br class='autobr' /&gt;
Joseph Larmarange et Fran&#231;ois Dabis &lt;br class='autobr' /&gt;
R&#233;sum&#233; &lt;br class='autobr' /&gt;
Les progr&#232;s observ&#233;s ces dix derni&#232;res ann&#233;es dans le champ de la pr&#233;vention du VIH, en particulier la place croissante prise par le traitement antir&#233;troviral, ont amen&#233; certains leaders politiques et scientifiques &#224; &#233;voquer la &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;fin du sida&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;, &#224; savoir un contr&#244;le des nouvelles infections et de la mortalit&#233; li&#233;e au VIH. Dans cet article, nous revenons en particulier sur l'objectif de contr&#244;le de la transmission sexuelle. Le traitement&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Publications-11-" rel="directory"&gt;Publications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Prevention-+" rel="tag"&gt;Pr&#233;vention&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Modelisation-+" rel="tag"&gt;Mod&#233;lisation&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Traitement-antiretroviral-ARV-98-98-+" rel="tag"&gt;Traitement antir&#233;troviral (ARV)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Treatment-as-Prevention-TasP-105-+" rel="tag"&gt;Treatment as Prevention (TasP)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Cascade-des-soins-+" rel="tag"&gt;Cascade des soins&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Universal-Test-Treat-UTT-+" rel="tag"&gt;Universal Test &amp; Treat (UTT)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-PrEP-+" rel="tag"&gt;PrEP&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH70/arton206-b36bc.png?1715208020' class='spip_logo spip_logo_right' width='150' height='70' alt=&#034;&#034; /&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Auteurs&lt;/h2&gt;
&lt;p&gt;Joseph Larmarange et Fran&#231;ois Dabis&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
R&#233;sum&#233;&lt;/h2&gt;
&lt;p&gt;Les progr&#232;s observ&#233;s ces dix derni&#232;res ann&#233;es dans le champ de la pr&#233;vention du VIH, en particulier la place croissante prise par le traitement antir&#233;troviral, ont amen&#233; certains leaders politiques et scientifiques &#224; &#233;voquer la &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;fin du sida&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187;, &#224; savoir un contr&#244;le des nouvelles infections et de la mortalit&#233; li&#233;e au VIH. Dans cet article, nous revenons en particulier sur l'objectif de contr&#244;le de la transmission sexuelle. Le traitement antir&#233;troviral pr&#233;coce des personnes infect&#233;es permet de r&#233;duire fortement la charge virale plasmatique et, par cons&#233;quent, la probabilit&#233; de transmettre le virus (treatment as prevention ou TasP). De m&#234;me, la prise d'antir&#233;troviraux par des personnes non infect&#233;es permet &#233;galement de les pr&#233;munir contre l'infection (prophylaxie pr&#233;exposition ou PrEP). La question aujourd'hui n'est plus de savoir quand utiliser ces m&#233;dicaments mais comment. Une strat&#233;gie de pr&#233;vention combin&#233;e pourrait r&#233;duire significativement les nouvelles infections, mais &#224; condition d'atteindre des niveaux de mise &#224; l'&#233;chelle non encore atteints &#224; ce jour. L'objectif de la fin du sida est atteignable, &#224; condition de ne pas succomber aux sir&#232;nes d'un &#8216;tout biom&#233;dical' et de mesurer pleinement les enjeux programmatiques, op&#233;rationnels, sociaux, comportementaux et politiques qui nous font face.&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
R&#233;f&#233;rence&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;PMKT34QK&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph and &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Dabis&lt;/span&gt; Fran&#231;ois (2017) &#8220;La fin du sida est-elle en vue ?&#8221;, &lt;span style=&#034;font-style: italic;&#034; &gt;Face &#224; face. Regards sur la sant&#233;&lt;/span&gt; (June 20). http://journals.openedition.org/faceaface/1160.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>
<item xml:lang="fr">
		<title>Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme&#160;: early findings of the ANRS 12249 TasP trial in rural South Africa</title>
		<link>https://www.joseph.larmarange.net/Factors-associated-with-194-194</link>
		<guid isPermaLink="true">https://www.joseph.larmarange.net/Factors-associated-with-194-194</guid>
		<dc:date>2016-08-17T14:10:11Z</dc:date>
		<dc:format>text/html</dc:format>
		<dc:language>fr</dc:language>
		<dc:creator>Joseph LARMARANGE</dc:creator>


		<dc:subject>VIH / SIDA</dc:subject>
		<dc:subject>Afrique du Sud</dc:subject>
		<dc:subject>&#201;pid&#233;miologie</dc:subject>
		<dc:subject>TasP (ANRS 12249)</dc:subject>
		<dc:subject>Traitement antir&#233;troviral (ARV)</dc:subject>
		<dc:subject>Treatment as Prevention (TasP)</dc:subject>
		<dc:subject>Universal Test &amp; Treat (UTT)</dc:subject>

		<description>
&lt;p&gt;Article published in an AIDS Care special issue&#160;: &#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;Test and Treat&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187; trials in Africa &lt;br class='autobr' /&gt; Authors &lt;br class='autobr' /&gt;
Sylvie Boyer, Collins Iwuji, Andr&#233;a Gosset, Camelia Protopopescu, Nonhlanhla Okesola, M&#233;lanie Plazy, Bruno Spire, Joanna Orne-Gliemann, Nuala McGrath, Deenan Pillay, Fran&#231;ois Dabis &amp; Joseph Larmarange on behalf of the ANRS 12249 TasP study group &lt;br class='autobr' /&gt;
Abstract &lt;br class='autobr' /&gt;
Prompt uptake of antiretroviral treatment (ART) is essential to ensure the success of universal test and treat (UTT) strategies to&#160;(&#8230;)&lt;/p&gt;


-
&lt;a href="https://www.joseph.larmarange.net/-Publications-11-" rel="directory"&gt;Publications&lt;/a&gt;

/ 
&lt;a href="https://www.joseph.larmarange.net/+-VIH-SIDA-+" rel="tag"&gt;VIH / SIDA&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Afrique-du-Sud-+" rel="tag"&gt;Afrique du Sud&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Epidemiologie-+" rel="tag"&gt;&#201;pid&#233;miologie&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-TasP-ANRS-12249-97-+" rel="tag"&gt;TasP (ANRS 12249)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Traitement-antiretroviral-ARV-98-98-+" rel="tag"&gt;Traitement antir&#233;troviral (ARV)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Treatment-as-Prevention-TasP-105-+" rel="tag"&gt;Treatment as Prevention (TasP)&lt;/a&gt;, 
&lt;a href="https://www.joseph.larmarange.net/+-Universal-Test-Treat-UTT-+" rel="tag"&gt;Universal Test &amp; Treat (UTT)&lt;/a&gt;

		</description>


 <content:encoded>&lt;img src='https://www.joseph.larmarange.net/local/cache-vignettes/L150xH113/arton194-d9c1c.jpg?1715360969' class='spip_logo spip_logo_right' width='150' height='113' alt=&#034;&#034; /&gt;
		&lt;div class='rss_chapo'&gt;&lt;p&gt;Article published in an &lt;i&gt;AIDS Care&lt;/i&gt; special issue&#160;: &lt;a href=&#034;http://www.tandfonline.com/toc/caic20/28/sup3&#034; class=&#034;spip_out&#034; rel=&#034;external&#034;&gt;&#171;&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;Test and Treat&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;&#187; trials in Africa&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div class='rss_texte'&gt;&lt;h2 class=&#034;spip&#034;&gt;
Authors&lt;/h2&gt;
&lt;p&gt;Sylvie Boyer, Collins Iwuji, Andr&#233;a Gosset, Camelia Protopopescu, Nonhlanhla Okesola, M&#233;lanie Plazy, Bruno Spire, Joanna Orne-Gliemann, Nuala McGrath, Deenan Pillay, Fran&#231;ois Dabis &amp; Joseph Larmarange on behalf of the ANRS 12249 TasP study group&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Abstract&lt;/h2&gt;
&lt;p&gt;Prompt uptake of antiretroviral treatment (ART) is essential to ensure the success of universal test and treat (UTT) strategies to prevent HIV transmission in high-prevalence settings. We describe ART initiation rates and associated factors within an ongoing UTT cluster-randomized trial in rural South Africa. HIV-positive individuals were offered immediate ART in the intervention arm vs. national guidelines recommended initiation (CD4&#8804;350&#8197;cells/mm3) in the control arm. We used data collected up to July 2015 among the ART-eligible individuals linked to TasP clinics before January 2015. ART initiation rates at one (M1), three (M3) and six months (M6) from baseline visit were described by cluster and CD4 count strata (cells/mm3) and other eligibility criteria&#160;: &#8804;100&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; 100&#8211;200&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; 200&#8211;350&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; CD4&gt;350 with WHO stage 3/4 or pregnancy&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; CD4&gt;350 without WHO stage 3/4 or pregnancy. A Cox model accounting for covariate effect changes over time was used to assess factors associated with ART initiation. The 514 participants had a median [interquartile range] follow-up duration of 1.08 [0.69&lt;small class=&#034;fine d-inline&#034;&gt;&#160;&lt;/small&gt;; 2.07] months until ART initiation or last visit. ART initiation rates at M1 varied substantially (36.9% in the group CD4&gt;350 without WHO stage 3/4 or pregnancy, and 55.2&#8211;71.8% in the three groups with CD4&#8804;350) but less at M6 (from 85.3% in the first group to 96.1&#8211;98.3% in the three other groups). Factors associated with lower ART initiation at M1 were a higher CD4 count and attending clinics with both high patient load and higher cluster HIV prevalence. After M1, having a regular partner was the only factor associated with higher likelihood of ART initiation. These findings suggest good ART uptake within a UTT setting, even among individuals with high CD4 count. However, inadequate staffing and healthcare professional practices could result in prioritizing ART initiation in patients with the lowest CD4 counts.&lt;/p&gt;
&lt;h2 class=&#034;spip&#034;&gt;
Reference&lt;/h2&gt;
&lt;p&gt;&lt;abbr class=&#034;unapi-id&#034; title=&#034;PTHADB96&#034;&gt;&lt;/abbr&gt;&lt;span class=&#034;csl-bib-body&#034;&gt;&lt;span class=&#034;csl-entry&#034;&gt;&lt;span style=&#034;font-variant: small-caps;&#034;&gt;Boyer&lt;/span&gt; Sylvie, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Iwuji&lt;/span&gt; Collins, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Gosset&lt;/span&gt; Andr&#233;a, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Protopopescu&lt;/span&gt; Camelia, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Okesola&lt;/span&gt; Nonhlanhla, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Plazy&lt;/span&gt; M&#233;lanie, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Spire&lt;/span&gt; Bruno, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Orne-Gliemann&lt;/span&gt; Joanna, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;McGrath&lt;/span&gt; Nuala, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Pillay&lt;/span&gt; Deenan, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Dabis&lt;/span&gt; Fran&#231;ois, &lt;span style=&#034;font-variant: small-caps;&#034;&gt;Larmarange&lt;/span&gt; Joseph and &lt;span style=&#034;font-variant: small-caps;&#034;&gt;group&lt;/span&gt; on behalf of the ANRS 12249 TasP study (2016) &#8220;Factors associated with antiretroviral treatment initiation amongst HIV-positive inspaniduals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa&#8221;, &lt;span style=&#034;font-style: italic;&#034; &gt;AIDS Care&lt;/span&gt;, 28 (sup3) (June 2), p.&#160;39-51. DOI&#160;: 10.1080/09540121.2016.1164808. http://dx.doi.org/10.1080/09540121.2016.1164808.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		
		</content:encoded>


		

	</item>



</channel>

</rss>
